Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel
NASDAQ:PLRZ

Polyrizon Q2 2026 Earnings Report

Polyrizon logo
$10.36 -0.41 (-3.81%)
Closing price 04:00 PM Eastern
Extended Trading
$10.50 +0.14 (+1.36%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Polyrizon EPS Results

Actual EPS
-$0.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Polyrizon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Polyrizon Announcement Details

Quarter
Q2 2026
Date
9/28/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Polyrizon Earnings Headlines

Polyrizon Files First-Half 2026 Results Showing Higher Assets and Wider Loss
 |  tipranks.comhttps://www.tipranks.com/news/company-announcements/polyrizon-files-first-half-2026-results-showing-higher-assets-and-wider-loss?utm_source=marketbeat.com&utm_medium=referral
Polyrizon Reports Enrollment Of First Patient In Trial For Allergy Nasal Spray NASARIX
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692968/polyrizon-reports-enrollment-of-first-patient-in-trial-for-allergy-nasal-spray-nasarix.aspx
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.tc pixel
September 28 at 1:00 AM  |  Monument Traders Alliance (Ad)
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366354/0/en/polyrizon-enrolls-first-patient-in-u-s-clinical-study-of-nasarix-pl-14-allergy-blocker.html
Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement
September 4, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=marketbeat.com&utm_medium=referral
Polyrizon Ltd. Closes $4 Million Registered Direct Offering and Concurrent Private Placement
September 4, 2026  |  quiverquant.comQ
See More Polyrizon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Polyrizon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Polyrizon and other key companies, straight to your email.

About Polyrizon

Polyrizon (NASDAQ:PLRZ) is an Israel-based biotechnology company developing hydrogel-based nasal products intended to provide localized protection in the nasal cavity. Its technology is designed to create a physical barrier that may help reduce exposure to airborne pathogens, allergens and other harmful particles before they enter the respiratory system.

The company’s platform focuses on nasal formulations and delivery systems that can adhere to the nasal mucosa and support applications in respiratory health. Potential product areas include protection against respiratory viruses, allergy-related symptoms and environmental pollutants, although the company’s products remain subject to development, testing and applicable regulatory requirements.

Polyrizon’s research and development activities are centered in Israel, with its products intended for potential use in international markets. The company’s technology is being developed for healthcare and consumer applications, but the availability, commercialization and regulatory status of specific products may vary by jurisdiction.

View Polyrizon Profile
Earnings Tools